Premium
Effects of anti‐arthritic drugs on proteoglycan synthesis by equine cartilage
Author(s) -
Frean S. P.,
Cambridge H.,
Lees P.
Publication year - 2002
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1046/j.1365-2885.2002.00404.x
Subject(s) - proteoglycan , cartilage , pharmacology , articular cartilage , chemistry , medicine , osteoarthritis , anatomy , pathology , alternative medicine
Effects of anti‐arthritic drugs on proteoglycan synthesis by equine cartilage. J. vet. Pharmacol. Therap. 25, 289–298. The concentration–effect relationships of phenylbutazone, indomethacin, betamethasone, pentosan polysulphate (PPS) and polysulphated glycosaminoglycan (PSGAG), on proteoglycan synthesis by equine cultured chondrocytes grown in monolayers, and articular cartilage explants were measured. The effect of PSGAG on interleukin‐1 β induced suppression of proteogycan synthesis was also investigated. Proteoglycan synthesis was measured by scintillation assay of radiolabelled sulphate ( 35 SO 4 ) incorporation. Polysulphated glycosaminoglycan and PPS stimulated proteoglycan synthesis in chondrocyte monolayers in a concentration‐related manner with maximal effects being achieved at a concentration of 10 μg/mL. Polysulphated glycosaminoglycan reversed the concentration‐related suppression of proteoglycan synthesis induced by interleukin‐1 β . Neither PSGAG nor PPS exerted significant effects on radiolabel incorporation in cartilage explants. Betamethasone suppressed proteoglycan synthesis by both chondrocytes and explants at high concentrations (0.1–100 μg/mL), but the effect was not concentration‐related. At low concentrations (0.001–0.05 μg/mL) betamethasone neither increased nor decreased proteoglycan synthesis. Phenylbutazone and indomethacin increased radiolabel incorporation in chondrocyte cultures but not in cartilage explants at low (0.1, 1 and 10 μg/mL), but not at high (20 and 100 μg/mL) concentrations. These findings may be relevant to the clinical use of these drugs in the treatment of equine disease.